{"id": "article-20657_0", "title": "Dopamine -- Continuing Education Activity", "content": "Dopamine is a peripheral vasostimulant used to treat low blood pressure, low heart rate, and cardiac arrest. Low infusion rates (0.5 to 2 micrograms/kg per minute) act on the visceral vasculature to produce vasodilation, including the kidneys, resulting in increased urinary flow. Intermediate infusion rates (from 2 to 10 micrograms/kg/min) stimulate myocardial contractility and increase electrical conductivity in the heart leading to increased cardiac output. Higher doses cause vasoconstriction and increased blood pressure via the adrenergic receptors alpha-1, beta-1, and beta-2, potentially leading to poor peripheral circulation. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of doxorubicin, pertinent for members of the interprofessional team in the treatment of patients with indicated conditions.", "contents": "Dopamine -- Continuing Education Activity. Dopamine is a peripheral vasostimulant used to treat low blood pressure, low heart rate, and cardiac arrest. Low infusion rates (0.5 to 2 micrograms/kg per minute) act on the visceral vasculature to produce vasodilation, including the kidneys, resulting in increased urinary flow. Intermediate infusion rates (from 2 to 10 micrograms/kg/min) stimulate myocardial contractility and increase electrical conductivity in the heart leading to increased cardiac output. Higher doses cause vasoconstriction and increased blood pressure via the adrenergic receptors alpha-1, beta-1, and beta-2, potentially leading to poor peripheral circulation. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of doxorubicin, pertinent for members of the interprofessional team in the treatment of patients with indicated conditions."}
{"id": "article-20657_1", "title": "Dopamine -- Continuing Education Activity", "content": "Objectives: Identify the mechanism of action at various doses of dopamine. Review the indications for therapy with dopamine. Outline the potential adverse effects of dopamine therapy. Summarize the importance of interprofessional communication and improving care coordination among the interprofessional team when initiating dopamine therapy. Access free multiple choice questions on this topic.", "contents": "Dopamine -- Continuing Education Activity. Objectives: Identify the mechanism of action at various doses of dopamine. Review the indications for therapy with dopamine. Outline the potential adverse effects of dopamine therapy. Summarize the importance of interprofessional communication and improving care coordination among the interprofessional team when initiating dopamine therapy. Access free multiple choice questions on this topic."}
{"id": "article-20657_2", "title": "Dopamine -- Indications", "content": "Dopamine\u00a0(DA)\u00a0is a peripheral vasostimulant used to treat low blood pressure, low heart rate, and cardiac arrest, especially in acute neonatal cases via a continuous intravenous drip. [1] Low\u00a0infusion rates (0.5 to 2 micrograms/kg per minute)\u00a0act on the visceral vasculature\u00a0to produce\u00a0vasodilation, including the kidneys,\u00a0resulting in increased urinary flow. Intermediate infusion rates (from 2 to 10 micrograms/kg/min) stimulate myocardial contractility and increase electrical conductivity in the heart leading to increased cardiac output.\u00a0 Higher doses cause vasoconstriction and\u00a0increased blood pressure via the adrenergic receptors alpha-1, beta-1, and beta-2, potentially leading to poor peripheral circulation. [2]", "contents": "Dopamine -- Indications. Dopamine\u00a0(DA)\u00a0is a peripheral vasostimulant used to treat low blood pressure, low heart rate, and cardiac arrest, especially in acute neonatal cases via a continuous intravenous drip. [1] Low\u00a0infusion rates (0.5 to 2 micrograms/kg per minute)\u00a0act on the visceral vasculature\u00a0to produce\u00a0vasodilation, including the kidneys,\u00a0resulting in increased urinary flow. Intermediate infusion rates (from 2 to 10 micrograms/kg/min) stimulate myocardial contractility and increase electrical conductivity in the heart leading to increased cardiac output.\u00a0 Higher doses cause vasoconstriction and\u00a0increased blood pressure via the adrenergic receptors alpha-1, beta-1, and beta-2, potentially leading to poor peripheral circulation. [2]"}
{"id": "article-20657_3", "title": "Dopamine -- Indications", "content": "Indications for DA\u00a0include maintenance of blood pressure for chronic congestive heart failure, trauma, renal failure, and even open-heart surgery and shock from myocardial infarction or septicemia. DA administration in low doses may also be beneficial to manage hypotension, low cardiac output, and inadequate organ perfusion (often indicated by low urine production). DA gained significant clinical importance in the central nervous system\u00a0(CNS) after Hornykiewicz's experiments showed its\u00a0reduction within the caudate nucleus of patients with Parkinson disease.\u00a0Furthermore,\u00a0the intravenous\u00a0administration of its\u00a0amino acid\u00a0precursor, L-DOPA ( L - dihydroxyphenylalanine) , attenuated the Parkinsonian symptoms. [3] Since the blood-brain barrier prohibits the crossing of\u00a0DA into the\u00a0CNS from the systemic circulation,\u00a0DA is ineffective on central neurological deficits such as Parkinson disease. However, L-DOPA successfully crosses the blood-brain barrier and can be administered systemically, including oral pills. Although the therapeutic replacement of dopamine effectively alleviates motor symptoms, it may lead to motor side-effects and behavioral issues associated with addiction (i.e., impulse control disorders.) [4]", "contents": "Dopamine -- Indications. Indications for DA\u00a0include maintenance of blood pressure for chronic congestive heart failure, trauma, renal failure, and even open-heart surgery and shock from myocardial infarction or septicemia. DA administration in low doses may also be beneficial to manage hypotension, low cardiac output, and inadequate organ perfusion (often indicated by low urine production). DA gained significant clinical importance in the central nervous system\u00a0(CNS) after Hornykiewicz's experiments showed its\u00a0reduction within the caudate nucleus of patients with Parkinson disease.\u00a0Furthermore,\u00a0the intravenous\u00a0administration of its\u00a0amino acid\u00a0precursor, L-DOPA ( L - dihydroxyphenylalanine) , attenuated the Parkinsonian symptoms. [3] Since the blood-brain barrier prohibits the crossing of\u00a0DA into the\u00a0CNS from the systemic circulation,\u00a0DA is ineffective on central neurological deficits such as Parkinson disease. However, L-DOPA successfully crosses the blood-brain barrier and can be administered systemically, including oral pills. Although the therapeutic replacement of dopamine effectively alleviates motor symptoms, it may lead to motor side-effects and behavioral issues associated with addiction (i.e., impulse control disorders.) [4]"}
{"id": "article-20657_4", "title": "Dopamine -- Mechanism of Action", "content": "Dopamine biosynthesis occurs following the same enzymatic sequence as norepinephrine (NE).\u00a0In fact, DA is\u00a0a precursor in the synthesis of NE (see Figure). [5] [6] The first step of\u00a0DA synthesis is rate-limiting and involves converting L-tyrosine to L-DOPA\u00a0by the enzyme tyrosine hydroxylase (TH) enzyme. [7] [8] [9] This conversion requires oxygen, an iron co-factor, and tetrahydrobiopterin (BH4 or THB) and results in adding a hydroxyl group to the aromatic ring to form L-DOPA. This molecule subsequently converts to\u00a0DA by the aromatic L-amino acid decarboxylase, involving removing the carboxyl group. Once synthesized, DA\u00a0is transported into synaptic vesicles via the vesicular monoamine transporter 2 (VMAT2) to the synaptic terminals. [10] [11] [12]", "contents": "Dopamine -- Mechanism of Action. Dopamine biosynthesis occurs following the same enzymatic sequence as norepinephrine (NE).\u00a0In fact, DA is\u00a0a precursor in the synthesis of NE (see Figure). [5] [6] The first step of\u00a0DA synthesis is rate-limiting and involves converting L-tyrosine to L-DOPA\u00a0by the enzyme tyrosine hydroxylase (TH) enzyme. [7] [8] [9] This conversion requires oxygen, an iron co-factor, and tetrahydrobiopterin (BH4 or THB) and results in adding a hydroxyl group to the aromatic ring to form L-DOPA. This molecule subsequently converts to\u00a0DA by the aromatic L-amino acid decarboxylase, involving removing the carboxyl group. Once synthesized, DA\u00a0is transported into synaptic vesicles via the vesicular monoamine transporter 2 (VMAT2) to the synaptic terminals. [10] [11] [12]"}
{"id": "article-20657_5", "title": "Dopamine -- Mechanism of Action", "content": "If an individual regularly consumes L-tyrosine in abundance, it\u00a0readily crosses the blood-brain barrier, as does L-DOPA. [13] . But its utility is\u00a0spatially restricted because DA cannot cross the blood-brain barrier.\u00a0However, if L-tyrosine levels are low, L-phenylalanine may be converted into L-tyrosine by phenylalanine hydroxylase.", "contents": "Dopamine -- Mechanism of Action. If an individual regularly consumes L-tyrosine in abundance, it\u00a0readily crosses the blood-brain barrier, as does L-DOPA. [13] . But its utility is\u00a0spatially restricted because DA cannot cross the blood-brain barrier.\u00a0However, if L-tyrosine levels are low, L-phenylalanine may be converted into L-tyrosine by phenylalanine hydroxylase."}
{"id": "article-20657_6", "title": "Dopamine -- Mechanism of Action", "content": "After DA release into the synaptic space,\u00a0it interacts with\u00a0various receptors on\u00a0the pre and post-synaptic terminals, causing neuronal excitation or inhibition\u00a0at the target neuron. There are two entire families of\u00a0DA receptors composed of five different isoforms, each\u00a0affecting different intracellular signaling pathways. [14] Both families of dopamine receptors, D1 and D2, are, by definition, G-protein-coupled receptors, but the D1 receptor class results in the neuron's depolarization,\u00a0whereas the D2 receptors inhibit neuronal firing. [15]", "contents": "Dopamine -- Mechanism of Action. After DA release into the synaptic space,\u00a0it interacts with\u00a0various receptors on\u00a0the pre and post-synaptic terminals, causing neuronal excitation or inhibition\u00a0at the target neuron. There are two entire families of\u00a0DA receptors composed of five different isoforms, each\u00a0affecting different intracellular signaling pathways. [14] Both families of dopamine receptors, D1 and D2, are, by definition, G-protein-coupled receptors, but the D1 receptor class results in the neuron's depolarization,\u00a0whereas the D2 receptors inhibit neuronal firing. [15]"}
{"id": "article-20657_7", "title": "Dopamine -- Mechanism of Action", "content": "Once in the synaptic cleft, DA\u00a0is\u00a0transported back into the pre-synaptic neuron via DA transporters (DAT) for repackaging or can remain in the extracellular space to be\u00a0taken up by glial cells or metabolized by the cellular membrane. DA may be metabolized extraneuronally by catechol-o-methyltransferase (COMT) to 3-methoxytyramine (3-MT), while monoamine oxidase-B (MAO-B) will rapidly metabolize 3-MT to homovanillic acid (HVA). [16] [17] Alternatively, it may undergo metabolism inside the cytoplasm, where the dual action of MAO-A and aldehyde dehydrogenase (ALDH) will convert DA to the phenolic acid\u00a03, 4-dihydroxyphenylacetic acid (DOPAC). [18]", "contents": "Dopamine -- Mechanism of Action. Once in the synaptic cleft, DA\u00a0is\u00a0transported back into the pre-synaptic neuron via DA transporters (DAT) for repackaging or can remain in the extracellular space to be\u00a0taken up by glial cells or metabolized by the cellular membrane. DA may be metabolized extraneuronally by catechol-o-methyltransferase (COMT) to 3-methoxytyramine (3-MT), while monoamine oxidase-B (MAO-B) will rapidly metabolize 3-MT to homovanillic acid (HVA). [16] [17] Alternatively, it may undergo metabolism inside the cytoplasm, where the dual action of MAO-A and aldehyde dehydrogenase (ALDH) will convert DA to the phenolic acid\u00a03, 4-dihydroxyphenylacetic acid (DOPAC). [18]"}
{"id": "article-20657_8", "title": "Dopamine -- Mechanism of Action", "content": "Given this complex sequence, the modulation of dopamine can occur at various levels, such as the entire neuron, its projections, or the neuronal circuitry across the nervous system. Also, during the synthesis of DA (transcriptional, translational, and post-translational regulation), synaptosomal packaging (regulation of VMAT, transport of vesicle to synapse), DA release (neuronal depolarization, calcium signaling, vesicle fusion), and via reuptake and metabolism through regulation of the respective enzymes and their spatial localization relative to their substrate. [18] [19]", "contents": "Dopamine -- Mechanism of Action. Given this complex sequence, the modulation of dopamine can occur at various levels, such as the entire neuron, its projections, or the neuronal circuitry across the nervous system. Also, during the synthesis of DA (transcriptional, translational, and post-translational regulation), synaptosomal packaging (regulation of VMAT, transport of vesicle to synapse), DA release (neuronal depolarization, calcium signaling, vesicle fusion), and via reuptake and metabolism through regulation of the respective enzymes and their spatial localization relative to their substrate. [18] [19]"}
{"id": "article-20657_9", "title": "Dopamine -- Mechanism of Action", "content": "As indicated earlier, the systemic action of DA is\u00a0subject to mediation by various receptors (D1, D2, D3, D4, and D5) and the alpha- and beta-adrenergic receptors.\u00a0These G-coupled receptors generally group as either D1 or D2, primarily based on their traditional biochemical functions showing that dopamine can modulate adenylyl cyclase activity. [6] [20] However, based on their molecular structure, biochemical properties, and pharmacological functions, DA receptors are further\u00a0classified either as D1-class (D1 and D5) or D2-class (D2, D3, D4). [21] [22] [23] [15]", "contents": "Dopamine -- Mechanism of Action. As indicated earlier, the systemic action of DA is\u00a0subject to mediation by various receptors (D1, D2, D3, D4, and D5) and the alpha- and beta-adrenergic receptors.\u00a0These G-coupled receptors generally group as either D1 or D2, primarily based on their traditional biochemical functions showing that dopamine can modulate adenylyl cyclase activity. [6] [20] However, based on their molecular structure, biochemical properties, and pharmacological functions, DA receptors are further\u00a0classified either as D1-class (D1 and D5) or D2-class (D2, D3, D4). [21] [22] [23] [15]"}
{"id": "article-20657_10", "title": "Dopamine -- Mechanism of Action", "content": "Activation of the D1 receptors on smooth muscle, the proximal renal tubule, and cortical collecting duct increase diuresis. [24] D2 receptors\u00a0are located pre-synaptically on the renal nerves and within the glomeruli and adrenal cortex. The activation of these nerves results in decreased renal sodium and water excretion. [25] Apomorphine is a\u00a0DA receptor agonist and may have similar activation on these DA\u00a0receptors. [26] Adrenergic receptors also bind\u00a0DA increasing arterial smooth muscle contraction and cardiac sinoatrial node conductivity,\u00a0which explains its cardiac therapeutic benefits.", "contents": "Dopamine -- Mechanism of Action. Activation of the D1 receptors on smooth muscle, the proximal renal tubule, and cortical collecting duct increase diuresis. [24] D2 receptors\u00a0are located pre-synaptically on the renal nerves and within the glomeruli and adrenal cortex. The activation of these nerves results in decreased renal sodium and water excretion. [25] Apomorphine is a\u00a0DA receptor agonist and may have similar activation on these DA\u00a0receptors. [26] Adrenergic receptors also bind\u00a0DA increasing arterial smooth muscle contraction and cardiac sinoatrial node conductivity,\u00a0which explains its cardiac therapeutic benefits."}
{"id": "article-20657_11", "title": "Dopamine -- Mechanism of Action", "content": "While the blood-brain barrier specifically restricts the transport of\u00a0DA\u00a0from the systemic circulation to the central nervous system, further research\u00a0has led to the discovery of its central role in reward-seeking behavior, wherein\u00a0its transmission becomes markedly increased. Current DA research includes epigenetic changes and their involvement\u00a0in a variety of psychiatric conditions,\u00a0including substance abuse and addiction,\u00a0schizophrenia, and attention deficit disorder. [27] [28] Altogether, these conditions involve disorders of\u00a0the mesolimbic and mesocortical\u00a0DA pathways. One common effect of addictive drugs in the CNS is the increased release of\u00a0DA in the striatum, classically associated with high locomotor activity and stereotypy. [29] [30] The striatal DA increase results from axon\u00a0projections arising directly from the pars compacta of the substantia nigra (SN)\u00a0and\u00a0the\u00a0ventral tegmental area (VTA), respectively, which project to the nucleus accumbens and amygdala, implicated in reward-stimulation and the fear-response. [29] [31] [32]", "contents": "Dopamine -- Mechanism of Action. While the blood-brain barrier specifically restricts the transport of\u00a0DA\u00a0from the systemic circulation to the central nervous system, further research\u00a0has led to the discovery of its central role in reward-seeking behavior, wherein\u00a0its transmission becomes markedly increased. Current DA research includes epigenetic changes and their involvement\u00a0in a variety of psychiatric conditions,\u00a0including substance abuse and addiction,\u00a0schizophrenia, and attention deficit disorder. [27] [28] Altogether, these conditions involve disorders of\u00a0the mesolimbic and mesocortical\u00a0DA pathways. One common effect of addictive drugs in the CNS is the increased release of\u00a0DA in the striatum, classically associated with high locomotor activity and stereotypy. [29] [30] The striatal DA increase results from axon\u00a0projections arising directly from the pars compacta of the substantia nigra (SN)\u00a0and\u00a0the\u00a0ventral tegmental area (VTA), respectively, which project to the nucleus accumbens and amygdala, implicated in reward-stimulation and the fear-response. [29] [31] [32]"}
{"id": "article-20657_12", "title": "Dopamine -- Mechanism of Action", "content": "Another DA circuit, the tuberoinfundibular pathway, is mainly responsible for regulating the neuroendocrine prolactin from the anterior pituitary gland, known for its role as a lactation inducer, but also has lesser roles in water/salt homeostasis and immune response and cell-cycle regulation. [33] [34] The nigrostriatal pathway is the main pathway involved in the motor deficits observed in Parkinson's disease. [35] This pathway comprises dopaminergic neurons\u00a0originating in the substantia nigra (pars compacta) and projects to the striatum via the medial forebrain bundle, forming synapses with several neuronal populations at the putamen, caudate nucleus, globus pallidus internus (GPi), and the subthalamic nucleus (STN), respectively. This elaborated network forms\u00a0the afferent connections of the substantia nigra to the circuitry involved in motor movement, namely the basal ganglia. In the latter, DA plays a\u00a0pivotal function in controlling\u00a0motor movement and learning new motor skills. [36]", "contents": "Dopamine -- Mechanism of Action. Another DA circuit, the tuberoinfundibular pathway, is mainly responsible for regulating the neuroendocrine prolactin from the anterior pituitary gland, known for its role as a lactation inducer, but also has lesser roles in water/salt homeostasis and immune response and cell-cycle regulation. [33] [34] The nigrostriatal pathway is the main pathway involved in the motor deficits observed in Parkinson's disease. [35] This pathway comprises dopaminergic neurons\u00a0originating in the substantia nigra (pars compacta) and projects to the striatum via the medial forebrain bundle, forming synapses with several neuronal populations at the putamen, caudate nucleus, globus pallidus internus (GPi), and the subthalamic nucleus (STN), respectively. This elaborated network forms\u00a0the afferent connections of the substantia nigra to the circuitry involved in motor movement, namely the basal ganglia. In the latter, DA plays a\u00a0pivotal function in controlling\u00a0motor movement and learning new motor skills. [36]"}
{"id": "article-20657_13", "title": "Dopamine -- Administration", "content": "For stimulation of the sympathetic nervous system, the indication is for a continuous intravenous drip administration. Dopamine\u00a0half-life in the systemic circulation is between 1 to 5 minutes; thus, slower forms of administration, such as oral administration,\u00a0are typically ineffective. [37]", "contents": "Dopamine -- Administration. For stimulation of the sympathetic nervous system, the indication is for a continuous intravenous drip administration. Dopamine\u00a0half-life in the systemic circulation is between 1 to 5 minutes; thus, slower forms of administration, such as oral administration,\u00a0are typically ineffective. [37]"}
{"id": "article-20657_14", "title": "Dopamine -- Administration", "content": "In addition\u00a0to its peripheral sympathetic effects,\u00a0DA is also critical for neurological movement function in Parkinson\u2019s disease. [35] L-DOPA administration is via the oral route, and after its\u00a0absorption,\u00a0a\u00a0small\u00a0percentage transports to the brain, where the neurons use it in the basal ganglia. L-DOPA \u00a0is\u00a0generally\u00a0administered concomitantly with carbidopa to inhibit the peripheral effects of L-DOPA in the sympathetic nervous system. Carbidopa is a decarboxylase inhibitor that prevents the systemic conversion of L-DOPA to\u00a0DA, which decreases the presentation of common side effects such as nausea and emesis. [38]", "contents": "Dopamine -- Administration. In addition\u00a0to its peripheral sympathetic effects,\u00a0DA is also critical for neurological movement function in Parkinson\u2019s disease. [35] L-DOPA administration is via the oral route, and after its\u00a0absorption,\u00a0a\u00a0small\u00a0percentage transports to the brain, where the neurons use it in the basal ganglia. L-DOPA \u00a0is\u00a0generally\u00a0administered concomitantly with carbidopa to inhibit the peripheral effects of L-DOPA in the sympathetic nervous system. Carbidopa is a decarboxylase inhibitor that prevents the systemic conversion of L-DOPA to\u00a0DA, which decreases the presentation of common side effects such as nausea and emesis. [38]"}
{"id": "article-20657_15", "title": "Dopamine -- Adverse Effects", "content": "Dopamine administration can adversely affect kidney function,\u00a0causing increased urinary flow and irregular heartbeat. [39] Excessive administration may cause deleterious conditions such as cerebrovascular accidents due to\u00a0elevated blood pressure in the\u00a0brain. [40]", "contents": "Dopamine -- Adverse Effects. Dopamine administration can adversely affect kidney function,\u00a0causing increased urinary flow and irregular heartbeat. [39] Excessive administration may cause deleterious conditions such as cerebrovascular accidents due to\u00a0elevated blood pressure in the\u00a0brain. [40]"}
{"id": "article-20657_16", "title": "Dopamine -- Adverse Effects", "content": "As previously stated, the neurotransmitter DA also acts centrally within the mesocorticolimbic pathway and has roles in processing reward and fear, as well as focusing attention and executive functioning, including complex planning. [31] [32] While systemic dopamine does not cross the blood-brain barrier,\u00a0central dopamine carries implications in somnolence, schizophrenia, addiction, and impulse control disorders. [13] [27] [41] Patients with neurologic\u00a0conditions using high doses of L-DOPA for Parkinson disease may\u00a0experience such\u00a0physiological alterations from the dysregulation of\u00a0DA within the CNS pathways.", "contents": "Dopamine -- Adverse Effects. As previously stated, the neurotransmitter DA also acts centrally within the mesocorticolimbic pathway and has roles in processing reward and fear, as well as focusing attention and executive functioning, including complex planning. [31] [32] While systemic dopamine does not cross the blood-brain barrier,\u00a0central dopamine carries implications in somnolence, schizophrenia, addiction, and impulse control disorders. [13] [27] [41] Patients with neurologic\u00a0conditions using high doses of L-DOPA for Parkinson disease may\u00a0experience such\u00a0physiological alterations from the dysregulation of\u00a0DA within the CNS pathways."}
{"id": "article-20657_17", "title": "Dopamine -- Contraindications", "content": "In patients with conditions of the heart or circulatory system, the intravenous administration of\u00a0dopamine is contraindicated. These\u00a0conditions\u00a0may include\u00a0ventricular arrhythmias and tachycardia, blood vessel blockage, low blood-oxygen content, decreased blood volume, acidosis, and adrenal gland dysfunctions resulting in high blood pressure such as pheochromocytoma. For patients recently treated with monoamine oxidase inhibitors,\u00a0DA\u00a0is\u00a0initially used in fractional doses (one-tenth\u00a0usual dose) and closely monitored for further effects. Medications to treat hypertension,\u00a0such as beta and alpha-adrenergic inhibitors, antagonize the therapeutic effects of DA. Haloperidol also blocks the systemic effects of DA. The anticonvulsant phenytoin has been reported\u00a0to cause hypotension and\u00a0decreased heart rate when used\u00a0with DA. On the other hand, tricyclic antidepressants increase the DA response,\u00a0similar to anesthetic agents such as cyclopropane and halogenated.\u00a0In combination with oxytocin, the use of DA can lead to chronic hypertension and may also cause cerebrovascular accidents. [42]", "contents": "Dopamine -- Contraindications. In patients with conditions of the heart or circulatory system, the intravenous administration of\u00a0dopamine is contraindicated. These\u00a0conditions\u00a0may include\u00a0ventricular arrhythmias and tachycardia, blood vessel blockage, low blood-oxygen content, decreased blood volume, acidosis, and adrenal gland dysfunctions resulting in high blood pressure such as pheochromocytoma. For patients recently treated with monoamine oxidase inhibitors,\u00a0DA\u00a0is\u00a0initially used in fractional doses (one-tenth\u00a0usual dose) and closely monitored for further effects. Medications to treat hypertension,\u00a0such as beta and alpha-adrenergic inhibitors, antagonize the therapeutic effects of DA. Haloperidol also blocks the systemic effects of DA. The anticonvulsant phenytoin has been reported\u00a0to cause hypotension and\u00a0decreased heart rate when used\u00a0with DA. On the other hand, tricyclic antidepressants increase the DA response,\u00a0similar to anesthetic agents such as cyclopropane and halogenated.\u00a0In combination with oxytocin, the use of DA can lead to chronic hypertension and may also cause cerebrovascular accidents. [42]"}
{"id": "article-20657_18", "title": "Dopamine -- Monitoring", "content": "Monitoring blood pressure and urine flow is necessary \u2014 monitoring of more advanced hemodynamic parameters such as cardiac output, including rhythm and pulmonary wedge pressure, is also recommended.\u00a0It is worth noting that dopamine agonists and mimetics that cross the blood-brain barrier interact with the neurological circuitry involved in motor, executive, and limbic functions, including addiction-linked reward systems, impulse control mechanisms, and arousal. Thus, the cessation of DA therapies may lead to a\u00a0condition called dopamine agonist withdrawal syndrome. This condition has wide-ranging symptoms, including anxiety, depression, panic attacks, fatigue, hypotension, nausea, irritability, and even suicidal ideations. [43] Therefore, recommendations are to taper patients off of these centrally acting\u00a0DA agonists.", "contents": "Dopamine -- Monitoring. Monitoring blood pressure and urine flow is necessary \u2014 monitoring of more advanced hemodynamic parameters such as cardiac output, including rhythm and pulmonary wedge pressure, is also recommended.\u00a0It is worth noting that dopamine agonists and mimetics that cross the blood-brain barrier interact with the neurological circuitry involved in motor, executive, and limbic functions, including addiction-linked reward systems, impulse control mechanisms, and arousal. Thus, the cessation of DA therapies may lead to a\u00a0condition called dopamine agonist withdrawal syndrome. This condition has wide-ranging symptoms, including anxiety, depression, panic attacks, fatigue, hypotension, nausea, irritability, and even suicidal ideations. [43] Therefore, recommendations are to taper patients off of these centrally acting\u00a0DA agonists."}
{"id": "article-20657_19", "title": "Dopamine -- Toxicity", "content": "According to \" Sax's Dangerous Properties of Industrial Materials \" (by Richard J. Lewis, 2004 - DOI: 10.1002/0471701343), studies in rodents\u00a0showed an LD50 (a lethal dose in 50% of subjects) between 59 to 163 mg/kg. In humans, dopamine can lead to peripheral vasoconstriction\u00a0resulting in gangrenous extremities and cardiac arrhythmias. [44] [45]", "contents": "Dopamine -- Toxicity. According to \" Sax's Dangerous Properties of Industrial Materials \" (by Richard J. Lewis, 2004 - DOI: 10.1002/0471701343), studies in rodents\u00a0showed an LD50 (a lethal dose in 50% of subjects) between 59 to 163 mg/kg. In humans, dopamine can lead to peripheral vasoconstriction\u00a0resulting in gangrenous extremities and cardiac arrhythmias. [44] [45]"}
{"id": "article-20657_20", "title": "Dopamine -- Enhancing Healthcare Team Outcomes", "content": "Dopamine administration\u00a0affects the cardiovascular system,\u00a0as well as other organs, including the kidneys and the brain. Contraindications include specific pharmaceutical agents, lifestyle, and nutrition factors that can impact similar organs with DA treatment. These factors and medications include psychopharmacological agents, neuroleptics, general anesthetics, and even physical therapy-induced cardiac challenges. Communication among all interprofessional healthcare team members, including clinicians, mid-level practitioners, nurses, pharmacists, and therapists, is critical to ensuring proper application of DA to\u00a0mitigate potentially harmful or chronic adverse effects while considering a holistic healthcare approach along with specific outcome objectives. By engaging in interprofessional teamwork and communication, dopamine therapy can achieve its best possible outcomes with the fewest adverse events. [Level 5]", "contents": "Dopamine -- Enhancing Healthcare Team Outcomes. Dopamine administration\u00a0affects the cardiovascular system,\u00a0as well as other organs, including the kidneys and the brain. Contraindications include specific pharmaceutical agents, lifestyle, and nutrition factors that can impact similar organs with DA treatment. These factors and medications include psychopharmacological agents, neuroleptics, general anesthetics, and even physical therapy-induced cardiac challenges. Communication among all interprofessional healthcare team members, including clinicians, mid-level practitioners, nurses, pharmacists, and therapists, is critical to ensuring proper application of DA to\u00a0mitigate potentially harmful or chronic adverse effects while considering a holistic healthcare approach along with specific outcome objectives. By engaging in interprofessional teamwork and communication, dopamine therapy can achieve its best possible outcomes with the fewest adverse events. [Level 5]"}
{"id": "article-20657_21", "title": "Dopamine -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Dopamine -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}